注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Lipella Pharmaceuticals Inc是一家临床阶段的生物技术公司。该公司专注于通过对现有仿制药中的活性剂进行重新配制并针对新应用优化这些重新配制来开发新药。该公司主要候选产品包括LP-10和 LP-310。LP-10是他克莫司的专有配方,经过优化可局部输送至膀胱。LP-310是他克莫司的另一种专有配方,经过优化可递送至口腔粘膜(口腔内壁的组织)和舌头表面。该公司正在开发LP-310用于治疗口腔扁平苔藓(OLP),这是一种影响口腔粘膜的慢性炎症。该公司开发了一种专有技术,称为其平台,该技术针对局部疏水药物输送到具有内皮表面的体腔进行了优化。其平台包括专为上皮组织使用而优化的专有药物输送技术。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Kamal Al-Eryani | - | 2023 | Member of Scientific Advisory Board |
Jonathan Kaufman | 57 | 2005 | Co-Founder, Chairman, CEO, President, Secretary & Treasurer |
Naoki Yoshimura | 67 | 2021 | Independent Director & Member of Advisory Board |
Daniel Cohen | 58 | 2023 | Independent Director |
Alessandro Villa | - | 2023 | Chair of the Scientific Advisory Board |
Michael B. Chancellor | 65 | 2005 | Co-Founder, Chief Medical Officer & Director |
Vidya Sankar | - | 2023 | Member of Scientific Advisory Board |
Ryan Pruchnic | 48 | 2021 | Independent Director |
Leaf Huang | - | - | Member of Advisory Board |
Herve Y. Sroussi | - | 2023 | Member of Scientific Advisory Board |
Roger Roman Dmochowski | - | - | Member of Advisory Board |
Lori A. Birder | 63 | 2023 | Independent Director |
William C. de Groat | - | - | Member of Advisory Board |
Michael Brennan | - | 2023 | Member of Scientific Advisory Board |
Byong Kim | 52 | 2022 | Independent Director |
Jason M. Hafron | - | 2024 | Member of Scientific Advisory Board |
Pradeep Tyagi | - | 2024 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核